

**FEMOROPOPLITEAL DISEASE
INCIDENCE OF RESTENOSIS
AFTER ENDOVASCULAR REVASCULARIZATION
AND REVIEW OF COST-EFFECTIVENESS ANALYSES**

Mary L. Yost
404-520-6652
THE SAGE GROUP

THE SAGE GROUP, LLC
RESEARCH AND CONSULTING
23 Ridge Rd
Beaufort SC 29907

Copyright Pending
2020

All rights reserved, including the right of reproduction
in whole or in part in any form.

REFERENCES (FIRST AND LAST PAGES)

1. Goodney PP, Beck AW, Nagle J, et al. National trends in lower extremity bypass surgery, endovascular interventions, and major amputations. *Journal of vascular surgery*. 2009 Jul 1;50(1):54-60.
2. Krishnan P, Faries P, Niazi K, et al. Stellarex drug-coated balloon for treatment of femoropopliteal disease: twelve-month outcomes from the randomized ILLUMENATE Pivotal and Pharmacokinetic Studies. *Circulation*. 2017;136(12):1102–1113.
3. Mohapatra A, Saadeddin Z, Bertges DJ, et al. Nationwide trends in drug-coated balloon and drug-eluting stent utilization in the femoropopliteal arteries. *Journal of Vascular Surgery*. 2020 Feb 1;71(2):560-6.
4. Garcia L, Jaff MR, Metzger C, et al. Wire-interwoven nitinol stent outcome in the superficial femoral and proximal popliteal arteries: twelve-month results of the SUPERB Trial [published correction appears in *Circ Cardiovasc Interv*. 2015 Jun;8(6). pii: e000014.
5. Laird JA. 3-Year Results of the RESILIENT Trial with the LifeStent: are the results of SFA stents durable? *Cath Lab Digest* 2013, Jan; 21(1). [Internet. Accessed 2020, July.] Available at: <https://www.cathlabdigest.com/articles/3-Year-Results-RESILIENT-Trial-LifeStent-Are-Results-SFA-Stents-Durable>.
6. Schroë H, Holden AH, Goueffic Y, et al. Stellarex drug-coated balloon for treatment of femoropopliteal arterial disease-The ILLUMENATE Global Study: 12-Month results from a prospective, multicenter, single-arm study. *Catheter Cardiovasc Interv*. 2018;91(3):497–504.
7. Micari A, Brodmann M, Keirse K, et al. Drug-coated balloon treatment of femoropopliteal lesions for patients with intermittent claudication and ischemic rest pain: 2-year results from the IN.PACT Global Study. *JACC Cardiovasc Interv*. 2018;11(10):945–953.
8. Banerjee S, Das TS, Abu-Fadel MS, et al. Pilot trial of cryoplasty or conventional balloon post-dilation of nitinol stents for revascularization of peripheral arterial segments: the COBRA trial. *J Am Coll Cardiol*. 2012;60(15):1352–1359.
9. Banerjee S, Jeon-Slaughter H, Armstrong EJ, et al. Clinical outcomes and cost comparisons of stent and non-stent interventions in infrainguinal peripheral artery disease: insights from the excellence in peripheral artery disease (XLPAD) Registry. *J Invasive Cardiol*. 2019;31(1):1–9.
10. Schneider PA. Evolution and current use of technology for superficial femoral and popliteal artery interventions for claudication. *J Vasc Surg*. 2017;66(3):916-923.
11. Burket MW. Restenosis and the new health care economy. *Endovascular Today* 2013, Aug. [Internet. Accessed 2020 July.] Available at: https://evtoday.com/pdfs/et0813_F5_Burket.pdf.
12. Pietzsch JB, Geisler BP, Garner AM, et al. Economic analysis of endovascular interventions for femoropopliteal arterial disease: a systematic review and budget impact model for the United States and Germany. *Catheter Cardiovasc Interv*. 2014;84(4):546–554.

139. Burket MW. Why drug eluting stents are cost effective in the superficial femoral artery. *Endovascular Today* 2013, Mar; Suppl:8-11. [Internet. Accessed 2020, Aug.] Available at: <https://evtoday.com/issues/2013-mar-supplement>.
140. Appendix. Salisbury AC, Li H, Vilain KR, et al. Cost-effectiveness of endovascular femoropopliteal intervention using drug-coated balloons versus standard percutaneous transluminal angioplasty: Results from the IN.PACT SFA II Trial. *JACC Cardiovasc Interv*. 2016 Nov 28;9(22):2343-2352. [internet. Accessed 2020, Aug.] Available at: <https://www.sciencedirect.com/science/article/pii/S1936879816314595>.
141. Supporting Information. Pietzsch JB, Geisler BP, Garner AM, et al. Economic analysis of endovascular interventions for femoropopliteal arterial disease: a systematic review and budget impact model for the United States and Germany. *Catheter Cardiovasc Interv*. 2014;84(4):546–554. [Internet. Accessed 2020, Aug.] Available at: <https://onlinelibrary.wiley.com/doi/abs/10.1002/ccd.25536>.
142. HealthKnowledge. Numbers needed to treat (NNTs) - calculation, interpretation, advantages and disadvantages. [Internet. Accessed 2020 July.] Available at: <https://www.healthknowledge.org.uk/public-health-textbook/research-methods/1a-epidemiology/nnts>.
143. Boston Scientific. Cardiovascular 2020 procedural payment guide. [Internet. Accessed 2020, July.] Available at: https://www.bostonscientific.com/content/dam/bostonscientific/Reimbursement/peripheral-intervention/pdf/Procedural_Payment_Guide.pdf.
144. Turley RS, Mi X, Qualls LG, et al. The effect of clinical care location on clinical outcomes after peripheral vascular intervention in Medicare beneficiaries. *JACC Cardiovasc Interv*. 2017 Jun 12;10(11):1161-1171.
145. CMS Transitional pass-through payment for drug-coated balloon reimbursement expires. *Endovascular Today* 2018, Jan 10. [Internet. Accessed 2020 Jun.] Available at: <https://evtoday.com/news/cms-transitional-pass-through-payment-for-drug-coated-balloon-reimbursement-expires>.
146. New CMS reimbursement code “severely underpays” for drug-coated balloons. *Vascular News* 2018, Mar 28. [internet. Accessed 2020 Jun.] Available at: <https://vascularnews.com/cms-reimbursement-dcb-drug-coated-balloons/>
147. Yost ML. Peripheral artery disease (PAD) interventional market analysis based on treatment with angioplasty or atherectomy. Atlanta (GA): THE SAGE GROUP; 2012.
148. Jens S, Conijn AP, Koelemay MJ, et al. Randomized trials for endovascular treatment of infrainguinal arterial disease: systematic review and meta-analysis (part 1: above the knee). *Eur J Vasc Endovasc Surg* 2014;47:524–35.

CONTACT INFORMATION

Mary L. Yost
President
Telephone (404) 520-6652
yost@thesagegroup.us